{"id":"placebo-oral-tablet-to-match-venetoclax","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo control, this tablet contains no active pharmaceutical ingredient and serves as a comparator in phase 3 trials to assess the efficacy and safety of venetoclax. It is designed to be indistinguishable from the active venetoclax tablet to maintain blinding in randomized controlled studies.","oneSentence":"This is a placebo tablet formulated to match the appearance and administration of venetoclax in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:24.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of venetoclax"}]},"trialDetails":[{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT03069352","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-23","conditions":"Acute Myeloid Leukemia (AML)","enrollment":211},{"nctId":"NCT02993523","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-02-02","conditions":"Acute Myeloid Leukemia (AML)","enrollment":443},{"nctId":"NCT03112174","phase":"PHASE3","title":"Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-06-19","conditions":"Mantle-Cell Lymphoma","enrollment":366},{"nctId":"NCT05079230","phase":"PHASE3","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-07","conditions":"Acute Myeloid Leukemia","enrollment":378},{"nctId":"NCT02910583","phase":"PHASE2","title":"Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2016-09-28","conditions":"Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":323},{"nctId":"NCT02755597","phase":"PHASE3","title":"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-11","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Oral tablet to match Venetoclax","genericName":"Placebo Oral tablet to match Venetoclax","companyName":"Pharmacyclics LLC.","companyId":"pharmacyclics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo tablet formulated to match the appearance and administration of venetoclax in clinical trials. Used for Control arm in phase 3 clinical trials of venetoclax.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}